Vivolight Medical Brings AI OCT-Powered One-Stop PCI Solution to EuroPCR 2026

Paris, France — May 19, 2026 — Vivolight Medical is pleased to announce its participation in EuroPCR 2026, taking place from May 19 to 22, 2026 at the Palais des Congrès de Paris. As one of the world’s leading gatherings for interventional cardiovascular field, EuroPCR brings together clinicians, researchers, innovators, and industry partners to exchange the latest advances, in intravascular imaging, physiological assessment, structural heart and other patient-centered cardiovascular care.

This year, artificial intelligence is taking a more prominent role across the interventional cardiology landscape, with growing attention on AI-enabled imaging, procedural planning, workflow optimization, and cath lab decision support. This direction is closely aligned with Vivolight’s continued focus on AI OCT — a next-generation concept designed to transform OCT from an imaging modality into an intelligent decision-support platform.

At EuroPCR 2025, Vivolight’s P80 Multimodal Cardiovascular OCT System attracted strong international attention for its image clarity, and innovative multimodal insights. Building on that momentum, Vivolight returns to EuroPCR 2026 with a sharper focus on AI OCT, presenting a one-stop PCI solution that integrates high-resolution OCT imaging, physiological assessment, plaque characterization, calcium assessment, and AI-powered analysis into one intelligent workflow.

Developed on Vivolight’s OCT platform, AI OCT is designed to integrate scattered intravascular imaging information — including lumen diameter, culprit lesion assessment, OCT-derived FFR, and plaque characteristics — into more comprehensive treatment strategies and actionable recommendations. Rather than simply displaying imaging data, AI OCT is built to help physicians move from information recognition to clinical interpretation, supporting more standardized, efficient, and evidence-based PCI decision-making.

The technical logic of AI OCT lies in the integration of imaging intelligence and clinical reasoning. In the imaging analysis layer, OCT-specific AI algorithms can assist with automated lumen segmentation, three-dimensional reconstruction, plaque characterization, vulnerable plaque identification, calcium assessment, stent-related evaluation, and OCT-derived functional assessment. These capabilities help convert complex intravascular images into structured, quantitative, and clinically meaningful data.

On top of this structured imaging foundation, AI OCT further connects compact AI models, domain-specific cardiovascular knowledge, high-quality clinical databases, and large-model reasoning. Through retrieval-augmented generation, the system can link imaging findings with relevant clinical evidence, expert consensus, helping generate recommendations that are more explainable and traceable. With local deployment, AI OCT is also designed to support data security, system stability, and real-time intraprocedural assistance.

The P80 Multimodal OCT Imaging System provides the hardware and imaging foundation for this intelligent workflow. Designed to deliver comprehensive, accurate, and real-time insights into vascular structures, P80 integrates multiple technologies into a single OCT platform and supports precise PCI decision-making through high-resolution imaging, automated diagnostic analysis, and multimodal lesion evaluation.

On the opening day of EuroPCR 2026, Vivolight’s booth has already attracted clinicians, distributors, and potential partners from Europe, India, the Middle East, and South America. Visitors experienced hands-on operation of the P80 system, explored its multimodal imaging and AI OCT capabilities, and engaged in in-depth discussions with the Vivolight team on clinical applications, market cooperation, and future collaboration opportunities.

As AI continues to reshape cardiovascular intervention, Vivolight believes the future of intravascular imaging lies not only in seeing more clearly, but also in understanding more deeply. P80 reflects this direction by helping transform OCT data into clinically meaningful information — supporting physicians as they assess lesions, plan strategies, and optimize PCI with greater efficiency and confidence.

At EuroPCR 2026, Vivolight invites clinicians, researchers, partners, and industry professionals to visit Booth M41 and experience how P80 and AI OCT are illuminating the next generation of image-guided PCI.

EuroPCR 2026
Date: May 19–22, 2026
Venue: Palais des Congrès de Paris, France
Booth: M41

Vivolight P80 — One-Stop PCI Solution Powered by AI OCT